NAD+: What the Human Evidence Actually Supports
NAD+ boosters reliably raise NAD+ in human trials. Whether that changes anything you would notice is a separate question, and the honest answer is not yet.
NAD+ is one of the most confidently marketed molecules in longevity medicine, and one of the most honestly uncertain. Both of those things are true at once, and the gap between them is where most of the confusion lives.
Here is the cleanest way to hold it. Human trials have established, fairly convincingly, that you can raise NAD+ in the body. They have not established that raising it changes anything you would notice. Those are different claims, and almost everything written about NAD+ blurs them.
What the trials actually measured
The most instructive study is a 2018 randomized, double-blind, placebo-controlled crossover trial published in Nature Communications by Martens and colleagues. It is worth walking through because it is well designed and because its results are frequently reported by half.
The design: two six-week periods, participants serving as their own controls. Twenty-four healthy adults aged 55 to 79 completed it, taking oral nicotinamide riboside, a precursor the body converts into NAD+.
The headline result was clear. NAD+ in peripheral blood mononuclear cells rose roughly 60 percent compared with placebo. A related marker, NAAD, rose nearly fivefold. The supplement did what it was supposed to do biochemically.
What the trials did not find
The same study measured a long list of things people actually care about. Systolic and diastolic blood pressure. Aortic stiffness. Carotid artery compliance. Flow-mediated dilation. Energy expenditure. Glucose control. Insulin sensitivity. Aerobic exercise capacity. Motor function.
After correction, none of them reached statistical significance.
The molecule went up. The outcomes did not follow. That is the actual state of the evidence, and it is rarely how you will see it described.
The authors were careful about this, and their own stated limitations are worth repeating. The cohort was small, too small to characterize safety broadly. The physiological outcomes were exploratory rather than primary endpoints, which means the study was not built to answer them. Participants were healthy with normal baseline function, so there was limited room to improve. There was no formal washout period between crossover phases. The authors flagged blood pressure and arterial stiffness as worth investigating further, which is a statement about future research, not a finding.
A later randomized trial in older adults with mild cognitive impairment reproduced the core biochemical result: nicotinamide riboside significantly raised blood NAD+ concentrations. The pattern holds. Raising NAD+ is the reliable part.
The distinction almost nobody makes
Nearly all of this human evidence involves oral nicotinamide riboside or related oral precursors. That matters more than it might seem.
NAD+ is also offered as an injection, which is a different route, different pharmacokinetics, and a different product. The oral precursor trials were not studying it. Evidence about one route is not automatically evidence about the other, and treating a nicotinamide riboside trial as support for an NAD+ injection is a substitution the data does not license.
Compounded NAD+ preparations are also not FDA approved and have not been evaluated by FDA for safety or effectiveness. That is a statement about regulatory status, not a verdict on whether they do anything.
So what should you take from this
Not that NAD+ is worthless. The biochemistry is real, the decline of NAD+ with age is a genuine area of study, and the research is ongoing and serious.
What you should take from it is calibration. If someone tells you NAD+ is clinically proven to improve energy, cognition, or aging, ask which trial, in whom, measuring what. The trials that exist have mostly shown that the molecule rises. The outcomes people are actually buying for have not been demonstrated in controlled human studies.
That may change. Trials are running, and the honest position today is uncertainty rather than dismissal.
If you are considering it, the useful conversation is with a provider who will tell you the same thing: this is an area where the marketing has run ahead of the evidence, and a decision here should be made with that clearly in view rather than around it.
Common questions
Does NAD+ actually work?
Human trials have shown fairly consistently that oral nicotinamide riboside raises NAD+ levels in the body. Those same trials have generally not shown significant improvements in the outcomes people take it for, such as blood pressure, glucose control, exercise capacity, or motor function. The biochemical effect is better established than any clinical benefit.
Is NAD+ injection the same as an oral NAD+ supplement?
No. Almost all of the human trial evidence involves oral precursors such as nicotinamide riboside. Injection is a different route with different pharmacokinetics, and the oral trials were not studying it. Results from one should not be read as evidence for the other.
Is compounded NAD+ FDA approved?
No. Compounded preparations are made by a licensed pharmacy for an individual patient and are not FDA approved or evaluated by FDA for safety and effectiveness. That is a regulatory fact and separate from the question of whether the research is promising.
Why does NAD+ get so much attention if the evidence is thin?
The underlying biology is genuinely interesting, NAD+ does decline with age, and the trials that exist reliably show the molecule can be raised. The gap is between that biochemical finding and demonstrated clinical benefit, and marketing tends to close that gap faster than the research does.
Sources
- 1.Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults — Nature Communications (PMID 29599478, PMC5876407), 2018
- 2.A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment — PubMed, PMID 37994989, 2023
